Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis

NCT07230353 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT07230353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07230353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 21, 2025
Completion date
June 30, 2028
Enrollment
68 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis